BALAXI PHARMACEUTICALS
|
BALAXI PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.01 | -6.70 | 50.82 | 48.18 | 37.23 |
| CEPS(Rs) | 4.88 | -0.05 | 9.37 | 9.63 | 7.69 |
| DPS(Rs) | - | - | - | 0.50 | - |
| Book NAV/Share(Rs) | 41.98 | 181.31 | 169.51 | 113.16 | 64.98 |
| Tax Rate(%) | 12.55 | 218.44 | 19.25 | 12.59 | 13.97 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.01 | 18.46 | 17.07 | 18.19 | 18.45 |
| EBIT Margin(%) | 11.17 | 1.98 | 17.33 | 19.79 | 19.28 |
| Pre Tax Margin(%) | 9.80 | 0.84 | 16.92 | 19.51 | 19.16 |
| PAT Margin (%) | 8.57 | -0.99 | 13.66 | 17.06 | 16.49 |
| Cash Profit Margin (%) | 9.22 | -0.12 | 14.18 | 17.24 | 16.61 |
| Performance Ratios | |||||
| ROA(%) | 8.82 | -0.96 | 22.09 | 34.52 | 56.23 |
| ROE(%) | 11.68 | -1.29 | 32.17 | 53.50 | 82.26 |
| ROCE(%) | 13.01 | 2.31 | 37.46 | 59.62 | 92.56 |
| Asset Turnover(x) | 1.03 | 0.97 | 1.62 | 2.02 | 3.41 |
| Sales/Fixed Asset(x) | 6.82 | 5.56 | 9.18 | 17.32 | 157.71 |
| Working Capital/Sales(x) | 1.55 | 1.55 | 2.40 | 3.59 | 3.92 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.15 | 0.18 | 0.11 | 0.06 | 0.01 |
| Receivable days | 103.86 | 81.67 | 43.31 | 68.14 | 84.00 |
| Inventory Days | 100.21 | 141.58 | 110.51 | 73.37 | 11.40 |
| Payable days | 49.80 | 90.14 | 75.41 | 69.04 | 31.52 |
| Valuation Parameters | |||||
| PER(x) | 12.75 | - | 2.09 | 7.30 | 14.09 |
| PCE(x) | 13.09 | -1,872.75 | 11.32 | 7.30 | 13.65 |
| Price/Book(x) | 1.52 | 2.74 | 3.13 | 3.11 | 8.07 |
| Yield(%) | - | - | - | 0.14 | - |
| EV/Net Sales(x) | 1.25 | 2.05 | 1.56 | 1.25 | 2.28 |
| EV/Core EBITDA(x) | 10.56 | 10.98 | 8.72 | 6.24 | 11.72 |
| EV/EBIT(x) | 11.17 | 103.70 | 8.98 | 6.30 | 11.80 |
| EV/CE(x) | 1.29 | 2.26 | 2.69 | 2.98 | 7.67 |
| M Cap / Sales | 1.21 | 2.24 | 1.60 | 1.26 | 2.27 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 21.25 | -28.28 | 20.42 | 20.77 | 406.95 |
| Core EBITDA Growth(%) | -23.46 | -24.78 | 7.63 | 24.25 | 407.44 |
| EBIT Growth(%) | 583.51 | -91.80 | 5.46 | 23.93 | 404.51 |
| PAT Growth(%) | 1,150.28 | -105.19 | -3.56 | 24.96 | 524.83 |
| EPS Growth(%) | 174.76 | -113.19 | 5.48 | 29.41 | 510.03 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.22 | 0.09 | 0.07 | 0.03 | 0.06 |
| Current Ratio(x) | 4.45 | 3.88 | 3.64 | 2.23 | 2.70 |
| Quick Ratio(x) | 3.01 | 2.36 | 1.67 | 0.67 | 2.31 |
| Interest Cover(x) | 8.15 | 1.73 | 42.34 | 72.69 | 160.34 |
| Total Debt/Mcap(x) | 0.15 | 0.03 | 0.02 | 0.01 | 0.01 |
Compare Financial Ratios of peers of BALAXI PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BALAXI PHARMACEUTICALS | ₹142.5 Cr | -9.2% | -24% | -67.3% | Stock Analytics | |
| ADANI ENTERPRISES | ₹278,922.0 Cr | -3.9% | -4.6% | -11.6% | Stock Analytics | |
| REDINGTON | ₹21,330.7 Cr | -5.7% | -3.8% | 35.1% | Stock Analytics | |
| MMTC | ₹9,543.0 Cr | -5% | 17.5% | -16.9% | Stock Analytics | |
| HONASA CONSUMER | ₹9,435.7 Cr | -4.3% | 11.9% | 18.2% | Stock Analytics | |
| LLOYDS ENTERPRISES | ₹9,142.5 Cr | -7.6% | 9.3% | 16.9% | Stock Analytics | |
BALAXI PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BALAXI PHARMACEUTICALS | -9.2% |
-24% |
-67.3% |
| SENSEX | -1.7% |
-1.4% |
7% |
You may also like the below Video Courses
